Roth Capital Starts ImmunoCellular Therapeutics (IMUC) at Buy - InvestingChannel

Roth Capital Starts ImmunoCellular Therapeutics (IMUC) at Buy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

Top NewsMost Read Highlighted

Get AlertsIMUC Hot Sheet

Rating Summary:

4 Buy, 0 Hold, 0 Sell

Rating Trend: Up

Today’s Overall Ratings:

Earlier, Roth Capital initiated coverage on ImmunoCellular Therapeutics (NYSE: IMUC) with a Buy. PT $6.00.

For an analyst ratings summary and ratings history on ImmunoCellular Therapeutics click here. For more ratings news on ImmunoCellular Therapeutics click here.

Shares of ImmunoCellular Therapeutics closed at $2.03 yesterday, with a 52 week range of $0.98-$3.96.

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items – JOIN NOW